Antibiotics are central to managing airway infections in cystic fibrosis (CF), yet current treatments often fail due to the presence of Pseudomonas aeruginosa biofilms, settling down the need for seeking therapies targeting biofilms. This study aimed to investigate the antibiofilm activity of aspartic acid and its potential as an adjuvant to tobramycin against P. aeruginosa biofilms formed by mucoid and small c...
P. aeruginosa é responsável pela elevada mortalidade e pelo estabelecimento de infeções crónicas em doentes com fibrose quística (FQ), principalmente devido à formação de biofilme. Várias abordagens terapêuticas, incluindo a combinação de antibióticos, têm sido utilizadas para tentar erradicar P. aeruginosa, no entanto, estas frequentemente falham. Dada a ineficácia dos antibióticos, tornou-se urgente desenvolv...
Pseudomonas aeruginosa is a major cause of chronic respiratory infections in patients with cystic fibrosis (CF), with biofilm formation contributing to its persistence and antibiotic resistance. This study aimed to gain insights into the mechanistic action of succinic acid as a ciprofloxacin adjuvant against clinically relevant CF isolates, including small colony variants and mucoid strains, and a ciprofloxacin...
Cystic fibrosis (CF) is a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane regulator resulting in thick mucus that difficults proper airflow. CF airways are infected by several opportunistic pathogens but P. aeruginosa is the major responsible for the high mortality rate due to the development of chronic infections. To long persist, P. aeruginosa uses sophisticated mechanisms t...